Understanding and treating systemic histiocytic neoplasms
Official title: Molecular Pathogenesis and Therapy of Systemic Histiocytic Neoplasms
Funded at Sloan-Kettering Inst Can Research · NIH-11063105 · Data updated 2026-11-12
This study is looking at rare blood disorders called systemic histiocytic neoplasms to understand how certain genetic changes, like the BRAFV600E mutation, affect them, and it aims to find better treatments using targeted therapies; if you're a patient with this condition, your response to these treatments will be closely monitored to help improve care for everyone.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2021 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $553,980 |
| NIH project number | 5R37CA259260-05 |
| Project ID | NIH-11063105 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with systemic histiocytic neoplasms, particularly those with BRAFV600E mutations or other related genetic alterations.
✕Less likely to help
Patients with histiocytic neoplasms that do not have identifiable genetic mutations or those with other unrelated conditions may not benefit from this research.
What this research studies
This research focuses on systemic histiocytic neoplasms, which are rare blood disorders affecting the monocyte/macrophage lineage. It investigates the genetic mutations that drive these conditions, particularly the BRAFV600E mutation, and explores targeted therapies like BRAF and MEK inhibitors. Patients will be monitored for their response to these treatments through blood tests that measure specific biomarkers, providing insights into the effectiveness of the therapies. The goal is to improve treatment outcomes for patients with these complex disorders.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with systemic histiocytic neoplasms, potentially improving their quality of life and survival rates.
How similar studies have gone: Previous research has shown success with targeted therapies for BRAFV600E-mutant histiocytic neoplasms, indicating a promising approach for similar conditions.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Diamond, Eli Lous — Sloan-Kettering Inst Can Research
- Study coordinator: Diamond, Eli Lous
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.